Recent 8-K filings for OGN

• April 30, 2026, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01 ◈ Earnings Releases

  Organon Q1 revenue $1.46B (-4% YoY); declares $0.02 dividend; Sun Pharma merger pending

  Revenue $1.460B, down 4% as-reported, down 9% ex-FX; Women's Health -16%, Biosimilars +23%.

• April 27, 2026, 7:59 PM ET M&A materiality 1.00 positive item 1.01item 5.02item 7.01item 9.01 ◈ Material Agreements

  Sun Pharma to acquire Organon for $14.00/share in all-cash deal; EV $11.75B

  Acquisition price $14.00/share in cash, a 103% premium to Organon's closing price on April 9, 2026.

• February 12, 2026, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01

  Organon reports FY2025 rev $6.2B (-3%), GAAP EPS $0.72; guides FY2026 rev ~$6.2B, Adj EBITDA ~$1.9B

  Full year 2025 revenue $6.2B, down 3% YoY; GAAP diluted EPS $0.72, adjusted diluted EPS $3.66.

• November 10, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01

  Organon Q3 revenue $1.6B, adj. EPS $1.01; FY2025 guidance lowered

  Q3 revenue $1.602B (+1% as-reported, -1% ex-FX); net income $160M vs $359M YoY (-55%).

• October 27, 2025, 7:59 PM ET leadership materiality 0.90 negative item 5.02item 8.01item 9.01

  Organon CEO resigns after probe finds improper Nexplanon wholesaler sales; Morrissey named interim CEO

  Kevin Ali resigned as CEO and Board member; no severance or equity retirement benefits.

• August 5, 2025, 7:59 PM ET earnings materiality 0.72 positive item 2.02item 7.01item 9.01

  Organon Q2 revenue $1.594B, adj. EPS $1.00; raises FY revenue guidance to $6.275-6.375B

  Revenue $1.594B, down 1% YoY; GAAP net income $145M ($0.56 EPS); non-GAAP adj. EPS $1.00, down 11% YoY.

• May 27, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  FDA designates Organon's HADLIMA as interchangeable biosimilar to Humira across all presentations

  FDA granted interchangeability for HADLIMA high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration prefilled syringe.

• May 1, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 7.01item 8.01item 9.01

  Organon cuts dividend 93% to $0.08/yr; Q1 revenue down 7%, adj EPS $1.02

  Q1 revenue $1.513B, -7% as-reported (-4% ex-FX); GAAP EPS $0.33, non-GAAP adj EPS $1.02.

• February 13, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01

  Organon FY2024 revenue $6.4B (+2%); guides FY2025 revenue $6.125-6.325B

  Full year 2024 revenue $6,401M (+2% as-reported, +3% constant currency); diluted EPS $3.33; non-GAAP adjusted diluted EPS $4.11.

• January 21, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

  Organon CCO Susanne Fiedler departs effective Jan 15, senior advisor until April 30

  Susanne Fiedler ceased performing CCO functions effective January 15, 2025.

• November 5, 2024, 6:59 PM ET regulatory materiality 0.60 neutral item 7.01item 9.01

  FDA extends VTAMA sNDA review for atopic dermatitis to March 12, 2025

  FDA extended target action date by 3 months to March 12, 2025; original date was December 12, 2024.

• October 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Organon Q3 revenue $1.582B (+4% YoY); narrows FY revenue guidance upward to $6.375-6.425B

  GAAP diluted EPS $1.38; non-GAAP adjusted diluted EPS $0.87 (includes $0.16 IPR&D charge).

• September 23, 2024, 7:59 PM ET M&A materiality 0.75 positive item 1.01item 9.01

  Organon acquires Dermavant Sciences for up to $1.2B; VTAMA drug portfolio

  Total consideration up to $1.2B: $175M upfront, $75M FDA milestone for atopic dermatitis, up to $950M commercial milestones.

• August 6, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01

  Organon Q2 2024 revenue flat at $1.607B; Adj. EPS $1.12, down 15% YoY

  Revenue $1.607B flat YoY (up 2% constant currency); net income $195M vs $242M prior year.

• May 17, 2024, 7:59 PM ET debt materiality 0.75 neutral item 1.01item 2.03item 9.01 ◈ Material Agreements ×2

  Organon issues $1B in senior notes, amends credit facilities to extend maturities and reduce rates

  Issued $500M 6.750% senior secured notes due 2034 and $500M 7.875% unsecured notes due 2034.

• May 2, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Organon Q1 2024 revenue up 5% to $1.62B; adjusted EPS $1.22, up 13% YoY; 2024 guidance reaffirmed

  Q1 revenue $1,622M (+5% as-reported, +7% constant currency); net income $201M (+14% YoY).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.69 · Most common event earnings

7 positive 6 negative 11 neutral

source · OGN on sec.gov